Wednesday, 21 December 2011

A look at Ranbaxy

Ranbaxy a leading Indian pharmaceutical, a number of issues have been cleared, FDI, compliance and the settlement of $500 million has given a boost, but short term profits are hit.

Some FX losses near 600 krore, USDINR.

380-390 range bound, currently trading below 400. If stock hits 380 buyers will enter

No comments:

Post a Comment